GTJA Investment Group
On July 10, Harbour BioMed announced completion of its Series C financing round of 102.8 million US dollars to accelerate the development of its innovative biopharmaceutical product pipeline targeting cancer, immunologic diseases, and COVID-19.
Lachesis recently announced that it has received 150 million yuan in the B + round of financing. The investors are Shenzhen Capital Group Company and GTJA Investment Group. It is worth noting that this is also the first financing event in the field of smart healthcare in 2020.